You are currently logged into
Hep Directory - My Account or Log Out
Hep Hep
  • Home
  • Basics
    • Basics
    • Introduction
    • Hepatitis A Virus
    • Hepatitis B Virus
    • Hepatitis C Virus
    • NAFLD/NASH
    • Alcoholic Liver Disease
    • Autoimmune Hepatitis
    • Primary Biliary Cholangitis
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Conferences
    • Hep Stories
    • Hep Slideshows
    • Hep TV
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • Opioids
    • Hep A Outbreak Map
    • Newly Diagnosed
    • Help Paying for Treatment
    • Hepatitis C Testing
    • Hepatitis C Medications
    • Hepatitis B Testing
    • Hepatitis B Treatment
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Bulk Subscriptions
    • Email Newsletter
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • Hep Stories
    • Hep Forums
    • Polls
    • Surveys
    • Ask Hep
    • Services Directory
    • Calendar
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Ziagen

Tweet
  • Share

How HIV Physicians Can Better Treat an Aging Population

A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.

The opening session of CROI 2018 in Boston.

The Best of CROI 2018

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

High Marks for Merck’s Hep C Treatment in Those With HIV

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Merck’s Hep C Drugs Show Promise for HIV Coinfection

Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.